Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 6/20 | 0.45 |
| ▸ | EGFR | P00533 | 5/20 | 0.38 |
| ▸ | ERBB2 | P04626 | 5/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.35 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.34 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4815952 | 0.78 | KDR (0.42) | KDRMAPK14MAP2K1FGFR1 | |
| SCHEMBL5606311 | 0.74 | KDR (0.42) | KDREGFRERBB2FGFR1 | |
| SCHEMBL7528805 | 0.74 | FGFR1 (0.41) | KDREGFRERBB2MAPK14FGFR1 | |
| SCHEMBL16645852 | 0.74 | KDR (0.42) | KDREGFRERBB2MAPK14MAP2K1 | |
| SCHEMBL16646778 | 0.71 | L3MBTL1 (0.40) | KDREGFR | |
| SCHEMBL1227597 | 0.69 | MAP2K1 (0.55) | KDREGFRERBB2MAPK14MAP2K1 | |
| SCHEMBL27888153 | 0.69 | EGFR (0.64) | EGFRERBB2 | |
| SCHEMBL27871866 | 0.68 | EGFR (0.55) | KDREGFRERBB2MAPK14 | |
| SCHEMBL27576858 | 0.68 | EGFR (0.62) | KDREGFRERBB2MAP2K1 | |
| SCHEMBL27871851 | 0.67 | EGFR (0.67) | KDREGFRERBB2MAP2K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1543009-A4 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2007-08-08 | — | — | EP | disclosed |
| US-20050234060-A1 | Pyrrolotriazine kinase inhibitors | BHIDE RAJEEV S | 2005-10-20 | — | — | US | disclosed |
| US-6951859-B2 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-10-04 | — | — | US | disclosed |
| EP-1543009-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2005-06-22 | — | — | EP | disclosed |
| US-20040063708-A1 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-01 | — | — | US | disclosed |
| WO-2004013145-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063708-A1 | Pyrrolotriazine kinase inhibitors | FGFR1, FLT1, FGFR2 | KDR 7/4885EGFR 80/4885ERBB2 11/4885 |
| US-20050234060-A1 | Pyrrolotriazine kinase inhibitors | FGFR1, FLT1, FGFR2 | KDR 7/4885EGFR 73/4885ERBB2 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.